Aaron G.l. Fletcher - 04 Apr 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Aaron G.L. Fletcher, Ph.D., by Kirk Allen Coleman, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 04 Apr 2022
Net transactions value: +$3,504,380
Form type: 4
Filing time: 04 Apr 2022, 18:34:53 UTC
Previous filing: 04 Apr 2022
Next filing: 17 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TFFP	Common Stock	Purchase	$3,215,000	+500,000		$6.43^*	500,000	04 Apr 2022	See footnote	F1
transaction	TFFP	Common Stock	Purchase	$289,380	+42,000	+8.4%	$6.89^*	542,000	04 Apr 2022	See footnote	F2
holding	TFFP	Common Stock						100,000	04 Apr 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. The reported shares were purchased in a private transaction from Lung Therapeutics, Inc. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
F2	The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. The reported shares were purchased in the open market in multiple transactions at prices ranging from $6.52 to $7.15. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.

Content

The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. The reported shares were purchased in a private transaction from Lung Therapeutics, Inc. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.

The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. The reported shares were purchased in the open market in multiple transactions at prices ranging from $6.52 to $7.15. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.